Addex Therapeutics Ltd. has released promising results from its novel γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) chronic cough program. In models of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback